42
Participants
Start Date
October 24, 2014
Primary Completion Date
June 4, 2020
Study Completion Date
June 4, 2020
Lapatinib
Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
Trastuzumab
Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
Aromatase Inhibitors (AIs)
Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
Novartis Investigative Site, Manila
Novartis Investigative Site, Vienna
Novartis Investigative Site, Cebu
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Donostia / San Sebastian
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
Novartis Investigative Site, Mobile
Novartis Investigative Site, Seville
Novartis Investigative Site, Valencia
Novartis Investigative Site, Valencia
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Phitsanulok
Novartis Investigative Site, Houston
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Ryazan
Novartis Investigative Site, Volzhskiy
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Itajaí
Novartis Investigative Site, Boston
Novartis Investigative Site, Berazategui
Novartis Investigative Site, Ciudad Autonoma de Buenos Aires
Novartis Investigative Site, Viedma
Novartis Investigative Site, Rosario
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Córdoba
Novartis Investigative Site, La Rioja
Novartis Investigative Site, San Miguel de Tucumán
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Salvador
Novartis Investigative Site, Belo Horizonte
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, Barretos
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São José do Rio Preto
Novartis Investigative Site, Pok Fu Lam
Novartis Investigative Site, Pokfulam
Novartis Investigative Site, Arequipa
Novartis Investigative Site, México
Novartis Investigative Site, Lima
Novartis Investigative Site, Moscow
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY